Table 1.
Patient characteristics stratified by baseline circulating tumor cell value
| Variable | Overall | CTC < 5 | CTC ≥ 5 | P value |
|---|---|---|---|---|
| All patients | 235 (100) | 141 (60) | 94 (40) | - |
| Age (years) | 53 (23 to 82) | 53 (28 to 82) | 53 (23 to 81) | 0.451 |
| Follow-up (months) | 18 (1 to 65) | 20 (1 to 65) | 18 (3 to 61) | - |
| HR+/HER-2 normal | 130 (55.3) | 74 (52.5) | 56 (59.6) | 0.349 |
| HR+/HER-2 overexpressed/amplified | 21 (8.9) | 15 (10.6) | 6 (6.4) | 0.352 |
| HR-/HER-2 overexpressed/amplified | 22 (9.4) | 13 (9.2) | 9 (9.6) | 1.0 |
| Triple receptor negative | 62 (26.4) | 39 (27.7) | 23 (24.4) | 0.651 |
| Visceral metastases | 140 (59.6) | 80 (56.7) | 60 (63.8) | 0.342 |
| Number of metastatic sites | ||||
| 1 | 85 (36.2) | 61 (43.3) | 24 (25.5) | 0.011* |
| 2 | 65 (27.6) | 38 (26.9) | 27 (28.8) | |
| ≥ 3 | 85 (36.2) | 42 (29.8) | 43 (45.7) |
Data presented as n (%) or median (range). CTC, circulating tumor cell; HER-2, human epidermal growth factor receptor-2; HR+, estrogen receptor-positive and/or progesterone receptor-positive; HR-, both estrogen receptor-negative and progesterone receptor-negative. * Statistical significant value.